somapacitan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
growth hormone derivatives	5413	1338578-34-9

Description:

Molecule	Description
Molfile Synonyms: somapacitan somapacitan-beco sogroya NNC0195-0092 NN8640	Somapacitan-beco is a human growth hormone (hGH) analog. It binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

somapacitan
somapacitan-beco
sogroya
NNC0195-0092
NN8640

Somapacitan-beco is a human growth hormone (hGH) analog. It binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin-like growth factor I (IGF-I) produced in the liver, while others are primarily a consequence of the direct effects of somapacitan-beco.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 31, 2021	EMA	Novo Nordisk A/S
Aug. 28, 2020	FDA	NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01AC07	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES Somatropin and somatropin agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Adult growth hormone deficiency	indication	421684006
Diabetic retinopathy	contraindication	4855003	DOID:8947
Malignant neoplastic disease	contraindication	363346000	DOID:162

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Growth hormone receptor	GPCR	P10912	GHR_HUMAN		Kd	8.04		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
D11194	KEGG_DRUG
8FOJ430U94	UNII
C4726770	UMLSCUI
JG5	PDB_CHEM_ID
CHEMBL3707290	ChEMBL_ID
129894493	PUBCHEM_CID
DB15093	DRUGBANK_ID
C000594654	MESH_SUPPLEMENTAL_RECORD_UI
018501	NDDF
898157004	SNOMEDCT_US
4042238	VANDF
4042239	VANDF
2557373	RXNORM
338169	MMSL
38779	MMSL
d09620	MMSL
C000718308	MESH_SUPPLEMENTAL_RECORD_UI
10019	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SOGROYA	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2030	INJECTION, SOLUTION	6.70 mg	SUBCUTANEOUS	BLA	31 sections
SOGROYA	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2030	INJECTION, SOLUTION	6.70 mg	SUBCUTANEOUS	BLA	31 sections
SOGROYA	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2035	INJECTION, SOLUTION	3.30 mg	SUBCUTANEOUS	BLA	31 sections
SOGROYA	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2035	INJECTION, SOLUTION	3.30 mg	SUBCUTANEOUS	BLA	31 sections
SOGROYA	HUMAN PRESCRIPTION DRUG LABEL	1	0169-2037	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	BLA	31 sections